Skip to main content
. Author manuscript; available in PMC: 2020 Jun 27.
Published in final edited form as: Behav Sleep Med. 2018 Dec 27;18(2):226–240. doi: 10.1080/15402002.2018.1557189

Figure 2.

Figure 2.

The within-subjects, randomized, two-treatment crossover protocol used for the study. Participants responded to the questionnaires assessing self-reported sleep (PSQI, MOS Sleep, ESS, PROMIS-SD, and PROMIS-SRI) and depression (PHQ-9) during the second weeks (2 and 16) of each baseline observation period (BL1 and BL2) and during the final weeks (10 and 24) of each intervention/control period. The Actiwatch was worn during the two baseline observation periods (weeks 1, 2, 15, and 16) and during the final weeks (10 and 24) of each intervention/control period. Participants wore a Daysimeter beginning 2 weeks prior to and through the duration of the study. The intervention/control periods were separated by a 4-week washout (W/O) period.